Hims challenges Novo Nordisk with affordable weight-loss pill launch
Hims launched a $49 weight-loss pill today to compete with Novo Nordisk. The move caused drugmakers' shares to fall as Novo vowed to take swift legal action.
洞察:
Hims & Hers Health, Inc. has launched a $49 compounded version of the oral Wegovy weight-loss pill, a move that directly undercuts the $199 price set by Novo Nordisk A/S . The introduction of this lower-priced alternative on February 5, 2026, has immediately created significant pricing pressure in the GLP-1 weight-loss market within the United States 
US.
US.The market reaction was swift and impactful, as shares of Novo Nordisk A/S fell 8.6% following the news. Eli Lilly and Company also experienced a sharp decline, with its shares dropping 6%. This sector-level volatility reflects investor concerns over the competitive landscape for weight-loss treatments as compounded versions enter the market at a fraction of the cost of branded drugs produced by companies in the United States US and Denmark 
DK.
US and Denmark DK.
